By helping scientists make data-driven decisions faster and more efficiently, artificial intelligence (AI) is revolutionizing drug discovery and development. Pathology is no exception and the Pathology Sciences team at AstraZeneca in Cambridge UK is leading the way. At AstraZeneca, Indica Labs’ HALO AI and other AI solution platforms are being used to examine digital pathology images for specific tissue classes, features and pathologies that are not easily quantified using traditional image analysis techniques or are too time-consuming for pathologists to quantify by eye.
While AI holds great promise in digital pathology, it is key to understand both the advantages and limitations of the technology in equal measure, the technical (hardware and software) requirements for different deployments and financial practicalities. In this one-hour webinar, Daniel Sutton will address these key points and will describe specific-use cases where AI has benefited pathology assessments and improved efficiency within his group at AstraZeneca. Prior to the main presentation, Dr. Kate Lillard Tunstall, Chief Scientific Officer at Indica Labs, will give a brief introduction to Indica Labs’ HALO AI solution.
Participants can select from 2 live broadcasts. Register below to attend on May 11, or click here to register for May 12.
Daniel Sutton, Senior Scientist, Digitisation and AI, Clinical Pharmacology and Safety Science, AstraZeneca
Daniel Sutton is a senior scientist in the Digitisation and AI group which is housed within the Clinical Pharmacology and Safety Science organisation at AstraZeneca UK. The group is focused on small scale toxicology studies and works at early stage research when image analysis support is required. Sutton joined AstraZeneca in 2015. He started his career in the NHS as a biomedical scientist in pathology before moving into the pharmaceutical industry as a research scientist at UCB and later at Novartis. Since then, he has worked in a wide range of companies from start-ups to multinationals in positions in pathology. During his career, Sutton has had the opportunity to work with many different image analysis and artificial intelligence platforms for digital pathology, including solutions from Definiens, Aperio, Visiopharm and Indica Labs.
Who Should Attend?
This webinar is recommended for pathologists, image analysts and research scientists with interest in –
- Quantitative assessment of digital pathology images
- Drug discovery research using tissues
- Pre-clinical safety assessment or toxicologic pathology
- Time savings in pathology evaluations for drug development
What You Will Learn
- How AI is used to quantify digital pathology images
- Different deployment models for AI in pathology
- How to identify projects that will benefit from AI
- How to validate AI solutions
- Four practical-use cases for AI in drug discovery and safety assessment
Indica Labs software solutions provide fast, quantitative evaluation of whole slide tissues using HALO® and HALO AITM for image analysis and HALO LinkTM and HALO APTM to manage images, data, and facilitate collaboration. With unmatched ease-of-use and scalability, pharmaceutical, healthcare, and research organizations worldwide are using HALO for high-throughput, whole-slide image quantification in areas such as oncology, immune-oncology, neuroscience, ophthalmology, metabolism, and toxicological pathology.